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Abstract
Purpose: Multimeric arginine-glycine-aspartic acid (RGD) peptides have advantages for imaging
integrin αvβ3 expression. Here, we compared the in vitro and in vivo behavior of three different
Ga-68-labeled multimeric Fusarinine C-RGD (FSC-RGD) conjugates, whereby RGD was
coupled directly, via a succinic acid or PEG linker (FSC(RGDfE)3, FSC(succ-RGD)3, FSC(Mal-
RGD)3). The positron emission tomography/X-ray computed tomography (PET/CT) imaging
properties were further compared using [68Ga]FSC(succ-RGD)3 with the monomeric [
68Ga]NO-
DAGA-RGD in a murine tumor model.
Procedure: FSC-RGD conjugates were labeled with Ga-68, and stability properties were
studied. For in vitro characterization, the partition coefficient, integrin αvβ3 binding affinity, and
cell uptake were determined. To characterize the in vivo properties, biodistribution studies and
microPET/CT were carried out using mice bearing either human M21/M21-L melanoma or
human U87MG glioblastoma tumor xenografts.
Results: All FSC-RGD conjugates were quantitatively labeled with Ga-68 within 10 min at RT.
The [68Ga]FSC-RGD conjugates exhibited high stability and hydrophilic character, with only
minor differences between the different conjugates. In vitro and in vivo studies showed
enhanced integrin αvβ3 binding affinity, receptor-selective tumor uptake, and rapid renal
excretion resulting in good imaging properties.
Conclusions: The type of linker between FSC and RGD had no pronounced effect on targeting
properties of [68Ga]FSC-RGD trimers. In particular, [68Ga]FSC(succ-RGD)3 exhibited improved
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properties compared to [68Ga]NODAGA-RGD, making it an alternative for imaging integrin αvβ3
expression.
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Introduction
Integrins are a family of cation-dependent heterodimeric
transmembrane adhesion receptors which are involved in
cell-cell, cell-extracellular matrix, and cell-pathogen inter-
actions. They are expressed on a variety of cell types and
play an important role in many aspects of tumor develop-
ment such as tumor-induced angiogenesis, tumor prolifera-
tion, and tumor cell migration [1]. Optimized cyclic
pentapeptides containing the arginine-glycine-aspartic acid
(RGD) motif show high affinity for the integrin αvβ3 as well
as remarkable metabolic stability [2, 3]. Versatile RGD-
based sequences, acyclic or cyclic, have been labeled with
halogens as well as with various radiometals to non-
invasively determine the integrin αvβ3 expression [4, 5].
Further studies have demonstrated that multimerization of
the RGD motif, i.e., combination of several RGD sequences
in one single molecule, can increase binding affinity leading
to enhanced target uptake and slower clearance from the
targeted tumor [6]. The first successful example allowing
noninvasive imaging of integrin αvβ3 expression is [
18F]Gal-
acto-RGD, which has been tested in preclinical studies and
clinical trials with good pharmacokinetics and receptor-
specific uptake [7–10]. However, the common problem
encountered for F-18 labeling is the complex and time-
consuming synthesis of these tracers with moderate yield
limiting routine use in the clinical setting.
To achieve an easier and more rapid radiosynthesis, with
high specific activity and high yield of the desired radiotracer,
an alternative approach is direct labeling with radiometals.
Therefore, the RGD peptides were modified with
corresponding chelator systems and radiolabeled with appro-
priate radiometals such as Ga-68, Cu-64, Y-86, and Zr-89 for
positron emission tomography (PET) imaging or Tc-99m and
In-111 for single-photon emission computed tomography
(SPECT) imaging. Of the nuclides mentioned above, Ga-68
has received tremendous attraction as a PET radionuclide due
to the ready availability from 68Ge/68Ga generator systems and
its physical characteristics with a half-life of 68 min and a high
positron yield of 89 %. This half-life is compatible with the
pharmacokinetics of many peptides including RGD peptides.
As a result of its significance for PET imaging, several
bifunctional chelators have been employed for Ga-68 labeling
of biomolecules including the most widely used cyclic
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) derivatives as well as 1,4,7-triaazacyclononane-
1,4,7-triacetic acid (NOTA) derivatives (e.g., NODAGA,
1,4,7-triazacyclononane-1,4-bis(acetic acid)-7-(2-glutaric
acid)), of which the later are better suited for the small Ga3+
ion due to their smaller cavity size. The higher complex
stability constant of the NOTA system allows radiolabeling
even at room temperature (RT) within minutes. [68Ga]NO-
DAGA-RGD is one promising monomeric compound showing
excellent in vitro and in vivo properties [11, 12]. Recently, a
multivalent bifuncational chelator named 1,4,7-triazacyclono-
nane-1,4,7-tris[(2-carboxyethyl)methylenephosphinic acid]
(TRAP) was developed and Ga-68-labeled TRAP(RGD)3
was reported to further improve integrin αvβ3 targeting as
compared to [68Ga]NODAGA-RGD [13]. Recently, we
reported that fusarinine C (FSC), a cyclic hydroxamate side-
rophore, is a promising Ga-68 and Zr-89 binding bifunctional
chelator [14–17]. FSC possesses three primary amine functions
allowing conjugation of up to three targeting vectors, thereby
facilitating the application of the multimerization approach.
FSC-based multimeric RGD conjugates (FSC(succ-RGD)3,
FSC(RGDfE)3, and FSC(Mal-RGD)3) were previously syn-
thesized via different conjugation strategies [14, 16]. In vitro
and in vivo evaluation of Zr-89-labeled FSC-RGD conjugates
demonstrated the superiority of FSC as a bifunctional chelator
for Zr-89 as well as the receptor specificity of [89Zr]FSC-RGD
conjugates [16]. However, the long physical half-life of Zr-89
(78.4 h) may be considered nonideal for the biological half-
lives of small RGD peptides which range from several minutes
to hours. By contrast, the 68-min half-life of Ga-68 matches
well with the biological half-lives of the cyclic RGD peptides.
As an excellent Ga-68 chelator, FSC complexation of Ga-68
occurs at RT resulting in high RCP and specific activity within
minutes [15].
In this study, FSC(succ-RGD)3, FSC(RGDfE)3, and
FSC(Mal-RGD)3 were labeled with Ga-68 and the compar-
ison of in vitro and in vivo properties including PET/CT
imaging of these compounds in a human melanoma tumor
model is reported for the first time. PET/CT imaging
properties of [68Ga]FSC(succ-RGD)3 were further compared
with the monomeric [68Ga]NODAGA-RGD in an alternative
human glioblastoma tumor model.
Materials and Methods
General
All described substances and solvents were of reagent grade and
were used without further purification. FSC(succ-RGD)3,
FSC(RGDfE)3, and FSC(Mal-RGD)3 were synthesized as described
earlier [16]. Milli-Q water was used for preparing all reagent
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solutions. Human melanoma M21 and M21-L cells were a kind gift
from D. A. Cheresh (Department of Pathology and the Moores
Cancer Center, University of California San Diego, La Jolla, CA,
USA), and human glioblastoma U87MG cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA).
Elution of the Ga-68 generator (IGG100, Eckert & Ziegler
Strahlen- und Medizintechnik AG, Berlin, Germany, nominal
activity 1850 MBq) was performed with 0.1-M HCl solution
(Rotem Industries Ltd., Beer-Sheva, Israel).
High-Performance Liquid Chromatography
An UltiMate 3000 (Thermo Fisher Scientific, Vienna, Austria)
high-performance liquid chromatography (HPLC) system consist-
ing of an UltiMate 3000 RS pump, a column oven (temperature
setting 25 °C) UV-vis variable wavelength detector (220 nm), and a
radioactivity detector (Raytest GABI, Raytest, Straubenhardt,
Germany) was used; gradient: acetonitrile (CH3CN)/H2O/0.1 %
trifluoroacetic acid (TFA) gradient: 0–0.5 min 0 % CH3CN, 0.5–
7.0 min 0–55 % CH3CN
Ga-68 Radiolabeling
The fraction containing the highest Ga-68 activity (approxi-
mately 400–500 MBq in 0.1 M HCl) was collected, and 110 μl
1.9-M NaOAc solution was added to adjust pH to 4.5. After
briefly shaking, 100 μl of the corresponding solution was
mixed with 30 μl of the FSC-RGD conjugates (1 μg/μl in
water; FSC(succ-RGD)3, 10.8 nmol; FSC(RGDfE)3, 12.0 nmol;
or FSC(Mal-RGD)3, 7.9 nmol) and incubated at RT for 10 min.
Analytical HPLC was used to confirm quantitative labeling.
Subsequently, the labeling solution was diluted with phosphate‐
buffered saline (PBS) and used for in vitro and in vivo studies
without further purification.
The labeling of NODAGA-RGD with Ga-68 was carried out as
described previously [11]. Briefly, to 100 μl of Ga-68 eluate
(approximately 40–50 MBq in 0.1 M HCl), 10 μl of NODAGA-
RGD (1 μg/μl in water, 10.4 nmol) was added and the pH of the
reaction solution was adjusted to 5 using 1.9-M NaOAc solution.
The solution was allowed to react for 15 min at RT. Subsequently,
the labeling solution with a radiochemical yield (RCY) higher than
96 % was diluted with PBS and used without further purification.
Stability Studies
The stability of [68Ga]FSC(succ-RGD)3, [
68Ga]FSC(RGDfE)3,
and [68Ga]FSC(Mal-RGD)3 was evaluated by incubating the
radiotracers in PBS, EDTA solution (pH 7; 91000-fold molar
excess of EDTA), and fresh human serum for up to 120 min,
respectively. At selected time points, aliquots of PBS or EDTA
solution were analyzed directly via RP-HPLC, while serum
aliquots were mixed with equal volumes of CH3CN, vortexed,
and centrifuged at 20,000 relative centrifugal force (rcf) for
2 min. Before analysis, the precipitate was washed three times
using CH3CN.
Distribution Coefficient (logD)
A volume of 500 μl PBS including 0.5 MBq radioligand
(approximately 0.5 μg peptide) was combined with 500 μl octanol;
the mixture was vortexed for 15 min and centrifuged for 2 min at
2000 rcf. From each phase, an aliquot (50 μl) was pipetted out and
measured in a 2480 Wizard2 Automatic Gamma Counter (Perki-
nElmer, Vienna, Austria). Each measurement was repeated five
times. LogD value was calculated as the average log ratio of the
radioactivity in the organic fraction and the PBS fraction.
Binding Affinity for Immobilized Integrin αvβ3
(Half Maximal Inhibitory Concentration Value)
In vitro binding affinities of cyclo(-Arg-Gly-Asp-DTyr-Val-)
(c(RGDyV)) and the three FSC-RGD conjugates were determined
by using isolated integrin αvβ3 (Millipore-Chemicon, Temecula,
CA, USA) and I-125-labeled c(RGDyV) as radioligand.
([125I]c(RGDyV) was produced as described in [18]). To integrin
αvβ3, coated overnight at 4 °C onto 96-well plates (Nunc, Thermo
Fisher Scientific, Vienna, Austria), [125I]c(RGDyV) and the
corresponding peptides in increasing concentrations from 0.001 to
100 nM were added. Plates were washed, and integrin bound
activity was recovered with 2-M NaOH solution and counted in a
gamma counter. OriginPro 8.5 software (Northampton, MA, USA)
was used to calculate half maximal inhibitory concentration (IC50)
values in three independent measurements.
Cell Culture
All cell lines were grown to confluence at 37 °C in a humidified
atmosphere of 95 % air/5 % carbon dioxide and split approximately
every 48 h. U-87 MG cells were cultured in tissue culture flasks
(Cellstar®; Greiner Bio-One, Kremsmuenster, Austria) using
EMEM supplemented with 10 % volume/volume (v/v) heat-
inactivated fetal bovine serum (FBS), 1 % v/v penicillin/streptomy-
cin/glutamine solution (PSG), 1 % v/v sodium pyruvate solution,
and 1 % v/v nonessential amino acid solution. M21 cells were
grown using DMEM supplemented with 10 % v/v FBS and 1 % v/v
PSG solution. M21-L cells were maintained in germ count dishes
(Greiner Bio-One) in RPMI 1640 cell culture medium containing
10 % FBS and 1 % PSG.
Internalization Assay
M21 cells (integrin αvβ3 positive) were diluted with RPMI 1640
(Gibco, Invitrogen Corporation, Paisley, UK) containing 1 %
glutamine (m/v), 1 % bovine serum albumin (BSA) (m/v), CaCl2
(1 mM), MgCl2 (1 mM), and MnCl2 (10 mM) to a concentration of
2.0 × 106 cells/ml. One-milliliter aliquots in Eppendorf tubes were
incubated at 37 °C for 1 h in triplicates, and [68Ga]FSC(succ-
RGD)3, [
68Ga]FSC(RGDfE)3, or [
68Ga]FSC(Mal-RGD)3 (approxi-
mately 1.5 × 106 cpm, 1.2 μg peptides) in PBS with 0.5 % BSA
(150 μl, total series) or with 10 μM c(RGDyV) in PBS/0.5 % BSA
(150 μl, nonspecific series) at 37 °C was added. After 90-min
incubation was stopped by centrifugation, the medium was
removed followed by washing (twice) with ice-cold Tris-buffered
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saline. After incubation in acid wash buffer (20 mM acetate
buffer, pH 4.5) at 37 °C for 5 min (two times) and
centrifugation, membrane bound activity was collected in
plastic vials. Internalized radioligand fraction was collected
after lysing cells by addition of 2 M NaOH. The internalized
activity was expressed as percentage of total activity per
milligram protein after spectrophotometric determination of
protein (Bradford assay) in the NaOH fraction.
Ex Vivo Biodistribution Studies
All animal experiments were approved by the Austrian Ministry
of Science (BMWF-66.011/000604-II/3b/2012 and BMWFW-
66.011/0049-WF/II/3b/2014) and the Czech Ministry of Educa-
tion Youth and Sports (MSMT-22421/2013-12) as well as by
the institutional Animal Welfare Committee of the Faculty of
Medicine and Dentistry of Palacky University in Olomouc and
conducted in compliance with the Austrian and Czech animal
protection laws.
For the induction of tumor xenografts, female, athymic BALB/c
nude mice (Charles River Laboratories) were injected subcutane-
ously with either 5 × 106 integrin αvβ3-positive M21 cells into the
right hind limb and with 5 × 106 integrin αvβ3-negative M21-L cells
(negative control) into the left hind limb of the same mouse.
Approximately 3 weeks after inoculation, the tumors had reached a
volume of 0.3–0.6 cm3. On the day of the experiment, [68Ga]FSC(-
succ-RGD)3, [
68Ga]FSC(RGDfE)3, or [
68Ga]FSC(Mal-RGD)3
(∼0.5 MBq/mouse, ∼0.5 μg peptide, respectively) was intrave-
nously injected in the lateral tail vein. Mice were euthanized by
cervical dislocation at 1 and 2 h (only for [68Ga]FSC(succ-RGD)3)
after injection. Organs (spleen, pancreas, stomach, intestine,
kidney, liver, heart, and lung), blood, muscle tissue, and tumors
were dissected and weighed. Activity of the different samples was
measured in the gamma counter. Results were expressed as
percentage of injected dose per gram tissue (% ID/g).
MicroPET/CT Imaging
To compare the imaging properties of [68Ga]FSC(succ-RGD)3,
[68Ga]FSC(RGDfE)3, and [
68Ga]FSC(Mal-RGD)3, microPET/CT
imaging experiments were conducted on an Inveon microPET/CT
scanner (Siemens Preclinical Solutions, Knoxville, USA). BALB/c
nude mice bearing M21-positive tumor xenografts were adminis-
tered with [68Ga]FSC(succ-RGD)3 (or [
68Ga]FSC(RGDfE)3,
[68Ga]FSC(Mal-RGD)3, ∼5 MBq/mouse, ∼5 μg peptide) via
intravenous (i.v.) injection. The body temperature of mice was
maintained at 37 °C on the scanner bed and in the incubation
chambers using heating pads. Dynamic 10-min duration PET scans
were performed for 50 min while static PET scans (10 min) were
performed at 1-h post-injection (p.i.), followed by a 25-min CT
scan (spatial resolution, 113 μm; 80 kV, 500 mA). The mice
remained under general anesthesia (isoflurane/O2) during the time
between injection and imaging. The microPET/CT scans were
reconstructed with Inveon Acquisition Workplace software (version
1.5; Siemens Preclinical Solutions), using a three-dimensional fast
maximum a posteriori algorithm with the following parameters:
matrix 256 × 256 × 161; pixel size 0.4 × 0.4 × 0.8 mm, and β-value
of 1.5-mm resolution with uniform variance. Spherical isocontours
were set at 50 % of the maximal pixel value to measure uptake
values (Bq/ml) in kidneys, heart, and tumor.
To investigate the capabilities of binding to the integrin αvβ3
receptors in the different tumor xenograft models and, at the same
time, compare the imaging properties of [68Ga]FSC(succ-RGD)3
and [68Ga]NODAGA-RGD, two U87MG tumor-bearing mice were
administered retro-orbitally (r.o.) [19] under general anesthesia with
[68Ga]FSC(succ-RGD)3 and [
68Ga]NODAGA-RGD each other
(∼6 MBq/mouse, ∼5 μg peptide) at continued days. For the
induction of tumor xenografts, female, athymic BALB/c nude mice
(AnLab, Prague, Czech Republic) were injected subcutaneously
with 5 × 106 U87MG cells into the right flank. The tumors were
allowed to grow until they had reached a volume of 0.5 to 0.8 cm3.
Imaging experiments were conducted on an Albira microPET/
SPECT/CT imaging system (Bruker Biospin Corporation, Wood-
bridge, CT, USA). MicroPET/CT images were acquired under
general anesthesia (isoflurane/O2) and heating at 37 °C. PET data
for each mouse was recorded via either dynamic imaging for
90 min (5-min PET scan per frame) or static scans (a 5-min PET
scan (axial FOV 148 mm) was performed, followed by a 25-min
CT scan (axial FOV 65 mm, 45 kVp, 400 μA, at 600 projections))
at 90 min p.i. The microPET/CT scans were reconstructed with
Albira software (Bruker Biospin Corporation, Woodbridge, CT,
USA) using maximum likelihood expectation maximization
(MLEM) and filtered backprojection (FBP) algorithms. Dead time,
decay correction, attenuation correction, and normalization were
applied to all PET data. The uptake values (%ID/g) in kidneys,
heart, and tumor were analyzed by drawing standardized volumes
of interest.
Statistical Analysis
Statistical analysis was performed using SPSS 17.0 software. The
biodistribution data was analyzed using Student’s t test. The level
of significance was set at PG 0.05.
Results
Radiolabeling and Stability Studies
All FSC-RGD conjugates were labeled with Ga-68 using
NaOAc buffer at pH 4.5 at RT within 10 min resulting in
almost quantitative labeling efficiency (998 %) and specific
activities ranging from 2.5 to 4 GBq/μmol. For all experi-
ments, the labeling solution was used without further
purification. Stability studies revealed high stability for all
three compounds in all examined media for up to 2 h,
indicating that the different conjugation strategies had no
detectable influence on the stability of Ga-68-labeled FSC
conjugates.
In Vitro Characterization
All three Ga-68-labeled FSC-RGD conjugates showed
hydrophi l ic proper t ies fo l lowing the order of
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[68Ga]FSC(RGDfE)3 (−3.8 ± 0.2) 9 [68Ga]FSC(succ-RGD)3
(−3.6 ± 0.1) 9 [68Ga]FSC(Mal-RGD)3 (−3.4 ± 0.0).
Binding of [125I]c(RGDyV to integrin αvβ3 was success-
fully displaced by all FSC-RGD conjugates and c(RGDyV)
in a concentration-dependent manner. IC50 values were 1.8
± 0.7 nM for FSC(succ-RGD)3, 2.1 ± 0.9 nM for
FSC(RGDfE)3, and 3.4 ± 0.6 nM for FSC(Mal-RGD)3,
indicating enhanced binding affinities as compared to
c(RGDyV) (6.2 ± 1.6 nM).
The internalization ability of Ga-68-labeled FSC-RGD
conjugates is shown in Fig. 1. The internalized activities
were 5.7 ± 0.6 % for [68Ga]FSC(succ-RGD)3, 5.3 ± 0.7 %
for [68Ga]FSC(RGDfE)3, and 3.0 ± 0.0 % for [
68Ga]FSC(-
Mal-RGD)3 of total activity per milligram protein
(% cpm/mg) after 90-min incubation. The corresponding
activities were reduced to 0.2 to 0.4 % cpm/mg of the
reference activity via addition of excess of c(RGDyV)
which demonstrated receptor-specific internalization.
Ex Vivo Biodistribution Studies
The data for the biodistribution studies of all three Ga-68-
labeled FSC-RGD conjugates in BALB/c nude mice bearing
both integrin αvβ3-positive (M21) as well as integrin αvβ3-
negative (M21-L) human melanoma tumors 1 h p.i. are
presented in Table 1 and the tumor to tissue ratios in Fig. 2.
The activity accumulation in the M21 tumor for the three
compounds is decreasing in the order: [68Ga]FSC(RGDfE)3
(5.49 ± 0.94 %ID/g) 9 [68Ga]FSC(succ-RGD)3 (3.69
± 0.94 %ID/g) 9 [68Ga]FSC(Mal-RGD)3 (2.62 ± 0.27 %ID/
g). The receptor-specific uptake is demonstrated by the
lower uptake found in the receptor-negative M21-L tumor
(1.10 ±0.30, 1.25 ± 0.06, 0.68 ± 0.09 %ID/g, respectively)
resulting in comparable M21/M21-L ratios for all three
compounds.
A statistical significant difference in the biodistribution
data of the three radioligands was observed only for spleen
and liver. [68Ga]FSC(succ-RGD)3 showed superior tumor to
tissue ratios in aforementioned organs compared to the other
two radioligands.
MicroPET/CT Studies
MicroPET/CT studies with BALB/c nude mice bearing
αvβ3-positive tumors were performed in order to compare
the imaging properties and the in vivo pharmacokinetics of
[68Ga]FSC(succ-RGD)3, [
68Ga]FSC(RGDfE)3, and
[68Ga]FSC(Mal-RGD)3. All three radioligands showed
receptor-specific uptake accompanied by predominantly
renal elimination at 1 h p.i., resulting in good image
contrasts (Fig. 3). In the static image of [68Ga]FSC(succ-
RGD)3, the αvβ3-positive tumor is clearly visualized with
high resolution whereas unspecific uptake of the radioligand
is minimal with the exception of the kidneys. To further
evaluate the imaging properties of [68Ga]FSC(succ-RGD)3,
dynamic PET imaging was performed and the time-activity
curves of tumor, kidney, and heart were extracted (Fig. 4).
Fig. 1 Internal izat ion of [68Ga]FSC(succ-RGD)3,
[68Ga]FSC(RGDfE)3, and [
68Ga]FSC(Mal-RGD)3 in integrin
αvβ3-positive M21 tumor cells.
Table 1. Biodistribution of [68Ga]FSC(succ-RGD)3, [
68Ga]FSC(RGDfE)3, and [
68Ga]FSC(Mal-RGD)3 at 1 h p.i. in BALB/c nude mice bearing integrin αvβ3-
positive tumors (M-21) on the right flank and integrin αvβ3-negative tumors (M21-L) on the left flank
Organ/tissue [68Ga]FSC(succ-RGD)3 (% ID/g) [
68Ga]FSC(RGDfE)3 (% ID/g) [
68Ga]FSC(Mal-RGD)3 (% ID/g)
Blood 0.63 ± 0.26 0.40 ± 0.08 0.36 ± 0.08
Spleen 3.27 ± 0.64 9.13 ± 0.27 3.48 ± 0.56
Pancreas 0.61 ± 0.13 1.04 ± 0.12 0.46 ± 0.07
Stomach 2.02 ± 1.35 4.76 ± 0.25 2.24 ± 0.17
Intestine 2.41 ± 0.80 3.21 ± 0.48 1.61 ± 0.30
Kidneys 8.12 ± 1.09 11.52 ± 1.87 5.77 ± 0.89
Liver 3.54 ± 0.63 12.09 ± 1.34 3.77 ± 0.95
Heart 1.21 ± 0.28 1.52 ± 0.13 0.70 ± 0.05
Lung 2.42 ± 0.22 2.48 ± 1.07 1.42 ± 0.26
Muscle 0.52 ± 0.19 0.94 ± 0.09 0.37 ± 0.08
M21 3.69 ± 0.94 5.49 ± 0.94 2.62 ± 0.27
M21-L 1.10 ± 0.30 1.25 ± 0.06 0.68 ± 0.09
Each data point represents an average of three to four animals
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The dynamic images allow visualization of the receptor-
positive tumor as early as 10 min p.i., confirming the rapid
accumulation of [68Ga]FSC(succ-RGD)3 in the tumor. The
time-activity curves of the kidneys and heart from dynamic
PET data showed rapid clearance of [68Ga]FSC(succ-RGD)3
from the circulation while the time-activity curve of the
tumor showed a clear tracer retention. To directly compare
the imaging properties of [68Ga]FSC(succ-RGD)3 and
[68Ga]NODAGA-RGD radiotracers, static (Fig. 5a) and
dynamic PET (Fig. 5b, c) imaging using mice bearing
U87MG xenograft tumors was carried out with both radio-
tracers. Three-dimensional volume projections of fused
microPET/CT static images for [68Ga]FSC(succ-RGD)3 and
[68Ga]NODAGA-RGD were carried out at 90 min p.i. by
two mice imaged per day on two consecutive days where on
day 1, mouse 1 received tracer A and mouse 2 tracer B and
vice versa. The dynamic microPET studies were carried out
in the same mouse by 5 min PET scan per frame over
90 min p.i. Both static and dynamic PET images showed
uptake in U87MG tumors of both radiotracers, however,
with improved tumor delineation for [68Ga]FSC(succ-
RGD)3. From the quantitative region of interest (ROI)
analysis, uptake values of [68Ga]FSC(succ-RGD)3 in tumor,
kidneys, and muscle were 3.8, 3.0, and 0.78 %ID/g at
90 min p.i., while the corresponding data for [68Ga]NO-
DAGA-RGD was 1.6, 1.0, and 0.32 %ID/g, respectively.
Despite an approximately 3-fold higher tumor uptake, tumor
to muscle (4.9 vs. 5) and tumor to kidney ratios (1.3 vs. 1.6)
are comparable.
Discussion
Many radiolabeled cyclic RGD peptides have been evalu-
ated as SPECT and PET radiotracers for imaging integrin
Fig. 2 Comparison of M21 melanoma to tissue ratios of
[68Ga]FSC(succ-RGD)3, [
68Ga]FSC(RGDfE)3, and [
68Ga]FSC(-
Mal-RGD)3 at 1 h p.i. M21/M21-L human melanoma xeno-
grafted nude mice were used. Significant differences in
uptake are marked with an asterisk (P G0.05).
Fig. 3 Three-dimensional volume projections of fused microPET/CT static images of a nude mouse bearing a M21 xenograft
tumor at 1 h p.i. a [68Ga]FSC(succ-RGD)3, b [
68Ga]FSC(RGDfE)3, and c [
68Ga]FSC(Mal-RGD)3. Red arrow: integrin αvβ3-positive
M21 tumor. Injected dose per mouse 5 MBq.
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αvβ3 expression. Among these tracers, radiolabeled multiva-
lent RGD peptides, mainly dimeric and tetrameric deriva-
tives, have been studied extensively on the basis of the
multivalency concept [6, 20]. These multimeric RGD
peptides exhibited improved receptor affinity due to the avidity
effect or simultaneous multivalent binding and prolonged
target retention due to increased tracer concentration compared
to that of their monomeric analogues. However, comparison of
dimeric and tetrameric cyclic RGD peptides showed superior-
ity of dimers over tetramers with respect to tumor to tissue
ratios [20]. The longer retention in nontarget tissues, mainly
due to higher molecular weight, results in slower elimination
which could not be compensated for by the higher tumor
uptake of tetrameric constructs. Recently, TRAP(RGD)3 was
reported as a trimeric RGD peptide for 68Ga labeling and
showed comparable tissue uptake to monomeric analogues but
significant enhanced tumor uptake providing the potential for
imaging of low-level integrin expression in tissues [13]. Based
on these findings, great attention should be taken to reach a
subtle balance between the tumor uptake and tumor to tissue
ratios.
Recently, we reported three FSC-based trimeric RGD
conjugates [16] labeled with Zr-89 showing excellent in
vitro stability. PET imaging of [89Zr]FSC(succ-RGD)3 in
BALB/c nude mice demonstrated receptor specificity of
FSC-RGD conjugates with high accumulation in αvβ3-
positive tumors whereas αvβ3-negative tumors were not
visualized during the 24 h monitoring period. To further
investigate these promising properties of these FSC-RGD
conjugates, we now describe the characterization and, in
particular, studies on the imaging properties of Ga-68-
labeled FSC-RGD conjugates in two tumor models includ-
ing static and dynamic imaging.
In the present study, all three FSC-RGD conjugates,
namely FSC(succ-RGD)3, FSC(RGDfE)3, and FSC(Mal-
RGD)3, were successfully labeled with Ga-68 following
the protocol that we reported previously [15]. Quantitative
labeling of FSC-RGD conjugates was performed at pH 4.5 at
RT within 10 min. The logD values of three Ga-68-labeled
FSC conjugates ranged from −3.4 to −3.8, displaying a more
hydrophilic character compared to their Zr-89-labeled
counterparts which ranged from −2.9 to −3.0 [16]. The
Fig. 4 a Dynamic PET imaging of [68Ga]FSC(succ-RGD)3 in a nude mouse bearing a M21 tumor xenograft. Injected dose
5 MBq. Red arrow: integrin αvβ3-positive M21 tumor. b The dynamic clearance curves of [
68Ga]FSC(succ-RGD)3 in selective
tissues over 45 min.
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difference of lipophilicity may result from the different net
charges of the radiolabeled compounds (the net charge of
[68Ga3+]FSC chelate itself is 0 while that of [89Zr4+]FSC
chelate is +1).
Competition studies demonstrated the enhanced binding
affinity of the multimeric FSC-RGD conjugates compared
with the monomeric c(RGDyV), with highest affinities for
FSC(succ-RGD)3 and FSC(RGDfE)3. This was further
confirmed by internalization assays with the Ga-68-labeled
FSC-RGD conjugates which result in much higher internal-
ization compared to [68Ga]NODAGA-RGD. The differences
in binding affinity and internalization properties between the
different conjugates can be attributed to the influence of the
different linkers (e.g., length and hydrophilicity), whereby
FSC(Mal-RGD)3 with the longest linker showed the lowest
affinity and lowest internalization values, whereas
FSC(succ-RGD)3 and FSC(RGDfE)3 were comparable.
Compared with Zr-89-labeled FSC-RGD conjugates [16],
Fig. 5 a Three-dimensional volume rendered projections of fused microPET/CT static images for [68Ga]FSC(succ-RGD)3 and
[68Ga]NODAGA-RGD at 90 min p.i. (two mice imaged per day on two consecutive days where on day 1, mouse 1 received
tracer A and mouse 2 tracer B and vice versa)). b Dynamic PET images of [68Ga]FSC(succ-RGD)3 and c [
68Ga]NODAGA-RGD in
the same mouse on two consecutive days. Scan duration 5-min PET scan per frame (18 frames). d Quantitative ROI analysis of
uptake of [68Ga]FSC(succ-RGD)3 and [
68Ga]NODAGA-RGD in tumor, kidneys, and muscle of the same BALB/c mice for 90 min
p.i. on two consecutive days. Mice bearing U87MG xenograft tumors; injected dose 6 MBq.
Table 2. Comparison of M21 to tissue ratios of [68Ga]FSC(succ-RGD)3 with literature data for [
68Ga]TRAP(RGD)3 [13] and [
68Ga]NODAGA-RGD
[68Ga]FSC(succ-RGD)3 [
68Ga]FSC(succ-RGD)3 [
68Ga]TRAP(RGD)3 [
68Ga]TRAP(RGD)3 [
68Ga]NODAGA-RGD
M21/tissue 1 h 2 h 1 h 2 h 1 h
M21/blood 6.4 ± 2.5 18.7 ± 2.7 19.4 ± 9.1 28.4 ± 19.6 11.3 ± 6.6
M21/spleen 1.1 ± 0.2 1.1 ± 0.1 1.8 ± 0.7 1.3 ± 0.7 0.9 ± 0.4
M21/pancreas 6.0 ± 0.4 10.7 ± 0.8 6.9 ± 1.9 5.7 ± 2.6 6.1 ± 3.1
M21/stomach 1.8 ± 1.3 1.8 ± 0.9 1.4 ± 0.6 1.3 ± 0.8 1.7 ± 0.7
M21/intestine 1.6 ± 0.4 1.9 ± 0.6 1.5 ± 0.7
M21/kidneys 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.2 0.5 ± 0.3 1.0 ± 0.4
M21/liver 1.0 ± 0.2 1.4 ± 0.2 1.2 ± 0.5 1.2 ± 0.7 0.8 ± 0.3
M21/heart 3.1 ± 0.8 6.2 ± 0.6 4.7 ± 2.4 3.2 ± 2.7 5.9 ± 2.4
M21/lung 1.5 ± 0.3 2.1 ± 0.1 2.1 ± 0.9 2.2 ± 1.3
M21/muscle 7.3 ± 0.8 14.4 ± 3.3 6.4 ± 1.9 6.9 ± 3.7 6.1 ± 3.5
M21/M21-L 3.4 ± 0.9 4.3 ± 2.2 4.1 ± 1.4 2.7 ± 1.6 4.0 ± 2.3
The same murine mouse model was used for all compounds. M21 to tissue ratios of [68Ga]NODAGA-RGD were calculated based on the literature data [14]
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the same trend of internalization is confirmed even though
the Zr-89-labeled compounds showed slightly lower inter-
nalization values than their Ga-68 counterparts.
The biodistribution data of [68Ga]FSC(succ-RGD)3,
[68Ga]FSC(RGDfE)3, and [
68Ga]FSC(Mal-RGD)3 in
BALB/c nude mice bearing integrin αvβ3-positive M21
tumors at 1 h p.i. were directly compared. All three
compounds exhibited target-specific binding with enhanced
tumor uptakes compared to [68Ga]NODAGA-RGD
(1.3 %ID/g [14]) and relative low uptakes in nontarget
tissue. PET studies revealed high-contrast images of the
αvβ3-positive M21 tumor at 1 h, confirming the biodistribu-
tion data (Table 1 and Fig. 3). Among the three compounds,
[68Ga]FSC(succ-RGD)3 showed superior tumor to tissue
ratios for spleen and liver, which is the reason that
[68Ga]FSC(succ-RGD)3 was chosen for further studies.
Comparing the tumor to tissue ratios of [68Ga]FSC(succ-
RGD)3 at 1 and 2 h p.i. (Fig. S1), increased tumor to
background ratios were found for the later time point
providing the potential for delayed imaging.
Biodistribution and tumor targeting of [68Ga]FSC(succ-
RGD)3 were very comparable to its Zr-89 counterpart [16].
Tumor and organ uptake values at 1 h p.i. were not
significantly different, an exception was a significantly
higher activity of the [68Ga]FSC-RGD conjugate in blood,
liver, spleen, and αvβ3-negative M21-L tumor, the later
tissues, however, minor in terms of absolute values. This
could be explained by a different biological behavior and
binding of released Ga-68 by transferrin resulting in longer
blood circulation. On the other hand, no indication of
differences in in vitro stability or protein binding of the
complexes was found and image contrast in microPET
images was excellent. Therefore, these differences could also
be related to the different net charges of the FSC chelate.
In Table 2, tumor to tissue ratios of [68Ga]FSC(succ-
RGD)3 are compared with the literature data of
[68Ga]TRAP(RGD)3 and [
68Ga]NODAGA-RGD. Overall,
very similar ratios are observed for [68Ga]FSC(succ-RGD)3
and [68Ga]TRAP(RGD)3 except for the tumor to blood ratio.
[68Ga]TRAP(RGD)3 exhibited higher ratios than
[68Ga]FSC(succ-RGD)3 at 1 and 2 h p.i., which is probably
due to a faster clearance from blood of [68Ga]TRAP(RGD)3.
Notably, the tumor to kidney ratios of [68Ga]FSC(succ-
RGD)3 and [
68Ga]TRAP(RGD)3 are almost the same,
indicating that the relative high kidney excretion is mainly
determined by the multimeric RGD peptide part and not the
chelator moiety. However, whereas for [68Ga]TRAP(RGD)3,
tumor to background ratios remained constant over time, for
our compound, tumor to background ratios improved up to
2 h p.i. again indicating an advantage of PET imaging at late
time points for [68Ga]FSC(succ-RGD)3. In particular, much
higher tumor to muscle ratios were observed (14.4 vs. 6.9 for
[68Ga]TRAP(RGD)3). Compared with the data found for
[68Ga]NODAGA-RGD, [68Ga]FSC(succ-RGD)3 exhibited
different tumor to tissue ratios for blood and kidney. Even
though not statistically significant, [68Ga]NODAGA-RGD
exhibited 1.8-fold higher tumor to blood and 2-fold
higher tumor to kidney ratios 1 h p.i. These differences
could be attributed to a slower blood clearance rate and
kidney excretion of [68Ga]FSC(succ-RGD)3. However,
they were not confirmed in PET imaging, where
comparable tumor to tissue ratios were found. The direct
comparison of [68Ga]FSC(succ-RGD)3 with [
68Ga]NO-
DAGA-RGD in mice bearing U87MG xenograft tumors
by static and dynamic PET imaging (Fig. 5) demon-
strated receptor-specific binding for both compounds.
Both Figs. 4 and 5d show not only enhanced tumor
accumulation (3.8 vs. 1.6 %ID/g, 90 min p.i.) but also
high retention of [68Ga]FSC(succ-RGD)3 in the receptor-
positive tumors during the observation period, which is
quite similar to the reported [68Ga]TRAP(RGD)3. In
contrast, washout of [68Ga]NODAGA-RGD from
U87MG xenografts was considerably faster, as can be
seen in the dynamic PET images. Whereas for
[68Ga]FSC(succ-RGD)3, no significant loss of image
contrast even at 90 min p.i. was found, [68Ga]NO-
DAGA-RGD exhibited significant decrease from 35 min
p.i. onward.
The enhanced tumor accumulation in addition to the good
tumor retention for [68Ga]FSC(succ-RGD)3 not only allows
PET imaging at late time points, but also provides the
possibility to achieve the same contrast using less radioac-
tivity, which is expected to reduce the radiation burden.
Moreover, it is of interest for small animal imaging where
the same image quality can be achieved with less radioac-
tivity injected.
Taking all these into account, [68Ga]FSC(succ-RGD)3 has
several advantages compared to [68Ga]NODAGA-RGD and
possibly to other monomeric RGD peptides. First, the
improved tumor accumulation allows for delayed imaging
with potentially improved image contrast; second, it pro-
vides the potential to use lower activity to reach the same
image contrast; third, the high affinity of [68Ga]FSC(succ-
RGD)3 provides the potential for imaging of low-level
integrin expression in tissues as Notni et al. mentioned [13].
Conclusion
Three trimeric FSC-RGD conjugates were quantitatively
labeled with Ga-68 within 10 min at RT. The Ga-68-labeled
compounds showed high stability in challenging solutions
and hydrophilic behavior. In vitro and in vivo studies
including PET/CT imaging demonstrated their high affinity
for the integrin αvβ3, receptor-selective tumor uptake, rapid
predominantly renal excretion, and excellent imaging prop-
erties. The comparison of [68Ga]FSC(succ-RGD)3 and
[68Ga]NODAGA-RGD shows the advantages of
[68Ga]FSC(succ-RGD)3 in respect of the possibility to carry
out delayed imaging with improved tumor to background
ratios, imaging with reduced radiation dose, and higher
binding affinity allowing monitoring of low-level integrin
expression in tissues.
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